Estrella Immunopharma Inc. (ESLA)

Estrella Immunopharma Inc. (ESLA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $23.3M; returns 1 day +35.5%, 1 week +129.1%, 1 year -57.7%.

Estrella Immunopharma, Inc. (ESLA) is a clinical-stage biopharmaceutical company focused on developing T-cell therapies for blood cancers and solid tumors in the United States. Their lead product candidate is EB103, currently in clinical trials for treating diffuse large B-cell lymphoma.

Groups ESLA belongs to

• Biotechnology
• Biopharmaceutical
• Clinical Stage
• Clinical Stage Biotech
• Immunotherapy
• Oncology
• Cancer Therapeutics
• Life Sciences
• Healthcare

ESLA financial model: income statement, cash flow and balance sheet